Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin.
M
M
Kurimoto
H
H
Matsuoka
N
N
Hanaoka
S
S
Uneda
T
T
Murayama
T
T
Sonoki
H
H
Nakakuma
D000617:Aminoglycosides / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077209:Decitabine; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D000079982:Gemtuzumab; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology*; D014407:Tumor Cells, Cultured
D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000077209:Decitabine; D000079982:Gemtuzumab; D001374:Azacitidine